169. メンケス病 Menkes disease Clinical trials / Disease details
臨床試験数 : 7 / 薬物数 : 7 - (DrugBank : 4) / 標的遺伝子数 : 9 - 標的パスウェイ数 : 14
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04977388 (ClinicalTrials.gov) | July 12, 2021 | 9/7/2021 | NORTHERA (DROXIDOPA) for Dysautonomia in Adult Survivors of Menkes Disease and Occipital Horn Syndrome | Phase I/II Study of NORTHERA (DROXIDOPA) for Dysautonomia in Adult Survivors of Menkes Disease and Adults With Occipital Horn Syndrome: Double-blind Placebo-controlled Randomized Crossover Clinical Trial | Menkes Disease;Occipital Horn Syndrome | Drug: Droxidopa;Other: Placebo | Stephen G. Kaler, MD | NULL | Recruiting | 18 Years | 50 Years | All | 6 | Phase 1/Phase 2 | United States |
| 2 | NCT04337684 (ClinicalTrials.gov) | December 1, 2019 | 1/4/2020 | Long Term Follow-up on Menkes Disease Patients | Long Term Follow-Up and Collection of Historical Control Data on Menkes Disease Patients | Menkes Disease | Drug: Long Term Follow-Up | Cyprium Therapeutics, Inc. | NULL | Enrolling by invitation | N/A | N/A | All | 50 | United States | |
| 3 | NCT04074512 (ClinicalTrials.gov) | October 15, 2019 | 27/8/2019 | Copper Histidinate Treatment for Menkes Disease | Copper Histidinate Treatment for Menkes Disease | Menkes Disease | Drug: Copper Histidinate | Cyprium Therapeutics, Inc. | NULL | Available | N/A | 6 Years | All | NULL | ||
| 4 | JPRN-UMIN000030626 | 2014/11/28 | 28/12/2017 | Investigation on the effectiveness of histidine copper treatment of Menkes disease patients | Menkes disease | Weekly,subcutaneous injection of histidine copper (750microgram once) is performed three times per week.It is continued every week until the end of the research during the research period. | Hamamatsu University School of Medicine | NULL | Complete: follow-up complete | Not applicable | Not applicable | Male and Female | 2 | Not selected | Japan | |
| 5 | JPRN-UMIN000005259 | 2011/03/03 | 18/03/2011 | Clinical trial of histidine-copper and diethyldithiocarbamate combination therapy for patients with Menkes disease | Menkes disease | give a dose of copper-histidine and diethyldithiocarbamate | Kobe Unniversitu Graduate School of Medicine | NULL | Complete: follow-up complete | Not applicable | Not applicable | Male and Female | 2 | Not selected | Japan | |
| 6 | NCT00811785 (ClinicalTrials.gov) | February 27, 2009 | 18/12/2008 | Molecular Bases of Response to Copper Treatment in Menkes Disease, Related Phenotypes, and Unexplained Copper Deficiency | Molecular Bases of Response to Copper Treatment in Menkes Disease, Related Phenotypes, and Unexplained Copper Deficiency | Menkes Disease;Occipital Horn Syndrome;Unexplained Copper Deficiency | Drug: Copper Histidine | Cyprium Therapeutics, Inc. | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);National Center for Complementary and Integrative Health (NCCIH) | Completed | N/A | 80 Years | All | 93 | Phase 3 | United States |
| 7 | NCT00001262 (ClinicalTrials.gov) | June 1990 | 3/11/1999 | Copper Histidine Therapy for Menkes Diseases | Early Copper Histidine Therapy in Menkes Disease | Kinky Hair Syndrome | Drug: Copper Histidine | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | NULL | Completed | N/A | N/A | All | 60 | Phase 1/Phase 2 | United States |